Template:Meropenem: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Ampicillin sulbactam}} | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
Meropenem is an ultra-broad spectrum injectable antibiotic used to treat a wide variety of infections, including meningitis and pneumonia. It is a beta-lactam and belongs to the subgroup of carbapenem, similar to imipenem and ertapenem. Meropenem was originally developed by Sumitomo Pharmaceuticals. It is marketed outside Japan by AstraZeneca with the brand names | '''Meropenem''' is an ultra-broad spectrum injectable [[antibiotic]] used to treat a wide variety of infections, including [[meningitis]] and [[pneumonia]]. It is a [[beta-lactam]] and belongs to the subgroup of [[carbapenem]], similar to [[imipenem]] and [[ertapenem]]. Meropenem was originally developed by [[Sumitomo Pharmaceuticals]]. It is marketed outside Japan by [[AstraZeneca]] with the brand names '''Merrem®''' and '''Meronem®'''. Other brand names include '''Mepem®''' (Taiwan) and '''Meropen®''' (Japan, Korea). It gained [[FDA]] approval in July 1996. It penetrates well into many tissues and body fluids including the [[cerebrospinal fluid]], [[bile]], [[heart valve]]s, [[lung]], and [[peritoneal]] fluid.<ref name=AHFS>{{ cite book | title= AHFS DRUG INFORMATION® 2006 | publisher= American Society of Health-System Pharmacists | date= 2006 | edition= 2006 ed }} </ref> | ||
==Category== | |||
Carbapenem | |||
==US Brand Names== | |||
Meronem, Merrem<sup>®</sup> | |||
==FDA Package Insert== | ==FDA Package Insert== | ||
| Line 22: | Line 29: | ||
'''| [[Meropenem other size packages available|Other Size Packages Available]]''' | '''| [[Meropenem other size packages available|Other Size Packages Available]]''' | ||
'''| [[Meropenem labels and packages|Labels and Packages]]''' | '''| [[Meropenem labels and packages|Labels and Packages]]''' | ||
==Mechanisms of Action== | |||
Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of | |||
vital cell wall components, which leads to cell death. | |||
Resistance | |||
===Mechanism of Resistance=== | |||
There are several mechanisms of resistance to carbapenems: 1) decreased permeability of the | |||
outer membrane of Gram-negative bacteria (due to diminished production of porins) causing | |||
reduced bacterial uptake, 2) reduced affinity of the target penicillin binding proteins (PBP), 3) | |||
increased expression of efflux pump components, and 4) production of antibiotic-destroying | |||
enzymes (carbapenemases, metallo-β-lactamases). | |||
===Cross-Resistance=== | |||
Cross resistance is sometimes observed with isolates resistant to other carbapenems. | |||
==References== | |||
{{Reflist|2}} | |||
[[Category:Antibiotics]] | |||
[[Category:Wikinfect]] | |||
Revision as of 19:43, 19 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Meropenem is an ultra-broad spectrum injectable antibiotic used to treat a wide variety of infections, including meningitis and pneumonia. It is a beta-lactam and belongs to the subgroup of carbapenem, similar to imipenem and ertapenem. Meropenem was originally developed by Sumitomo Pharmaceuticals. It is marketed outside Japan by AstraZeneca with the brand names Merrem® and Meronem®. Other brand names include Mepem® (Taiwan) and Meropen® (Japan, Korea). It gained FDA approval in July 1996. It penetrates well into many tissues and body fluids including the cerebrospinal fluid, bile, heart valves, lung, and peritoneal fluid.[1]
Category
Carbapenem
US Brand Names
Meronem, Merrem®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings | Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Other Size Packages Available | Labels and Packages
Mechanisms of Action
Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death. Resistance
Mechanism of Resistance
There are several mechanisms of resistance to carbapenems: 1) decreased permeability of the outer membrane of Gram-negative bacteria (due to diminished production of porins) causing reduced bacterial uptake, 2) reduced affinity of the target penicillin binding proteins (PBP), 3) increased expression of efflux pump components, and 4) production of antibiotic-destroying enzymes (carbapenemases, metallo-β-lactamases).
Cross-Resistance
Cross resistance is sometimes observed with isolates resistant to other carbapenems.
References
- ↑ AHFS DRUG INFORMATION® 2006 (2006 ed ed.). American Society of Health-System Pharmacists. 2006.